Jason Zhu

<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Landon C. Brown, Matthew D. Tucker, Ramy Sedhom et al. · Journal for ImmunoTherapy of Cancer · 2021 · 113 citations · Full text

Life Sciences, Immunology, Oncology +17

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline et al. · Journal for ImmunoTherapy of Cancer · 2019 · 107 citations · Full text

Medicine, Immunology, Oncology +17

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

Matthew Labriola, Jason Zhu, Rajan T. Gupta et al. · Journal for ImmunoTherapy of Cancer · 2020 · 100 citations · Full text

Medicine, Immunology, Oncology +17

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Jeffrey M. Conroy, Sarabjot Pabla, Mary Nesline et al. · Journal for ImmunoTherapy of Cancer · 2019 · 90 citations · Full text

Life Sciences, Oncology, Pathology +17

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

Matthew D. Tucker, Jason Zhu, Daniele Marin et al. · Cancer Medicine · 2019 · 80 citations · Full text

Medicine, Oncology, Urology +17